A number of clinical trials in noncolorectal gastrointestinal cancers have opened in recent months. Maybe one of your patients could benefit from being enrolled? Locally advanced or metastatic hepatocellular carcinoma (HCC). Adult patients with biopsy-proven advanced hepatocellular cancer who have failed on two systemic therapies are sought for a phase 2 trial testing an electromagnetic treatment device called TheraBionic. Participants will have a 1-hour session with the device at the cancer center, then will take the device home and self-administer three 1-hour treatments a day for up to 2 years, with clinic visits every 6 weeks.
Author: Praveen Suthrum
A distinct gut microbiome signature has been identified in people with IBS who are responsive to low FODMAP dietary therapy. And if confirmed in further studies, the unique gut microbiome subtypes found in IBS may be useful as a biomarker to enable clinicians to select patients who are likely to be suitable or unsuitable for FODMAP therapy, according Australian expert Professor Peter Gibson. In the study, published in Gut, UK researchers analysed the taxonomic and functional profiles of the stool microbiota from 56 people with IBS, and compared these with control subjects from the same household.
Iterative Scopes, a pioneer in the development of precision-based gastrointestinal disease technologies, announced today that it has CE marked its SKOUT medical device under the MDD (Directive 93/42/EEC) after successfully completing the assessment of the conformity of the device with the applicable MDD requirements in April 2021.1 This milestone marked the product’s first regulatory certification and will enable its distribution and marketing in Europe, a key step in Iterative Scopes’ global expansion plans. SKOUT is an artificial intelligence (AI) driven medical device intended to detect potential colorectal polyps during colonoscopy examinations in adult patients undergoing colorectal cancer screening or surveillance.2…
The value of colonoscopy for colorectal cancer screening is important from the perspective of the business aspect and also patient care aspect, according to a speaker at GI Outlook. “I chose the value of colonoscopy because it’s an important topic at the local level, both from the perspective of the practice, the patients and competitive technologies,” Joseph J. Vicari, MD, MBA, FASGE, of Rockford Gastroenterology Associates in Illinois, said during the presentation.
Patients needing colonoscopy after a non-invasive, stool-based test (SBT) often paid out of pocket for it, a study showed. One in six older adults who had a colonoscopy in the 6 months after some form of SBT ended up with cost-sharing, including 48% of commercially insured and 78% of Medicare patients in the insurance database claims analysis. Those out-of-pocket costs ranged from $99 to $231, reported Nicole Princic, MS, of IBM Watson Health in Cambridge, Massachusetts, and colleagues in a research letter in JAMA Network Open.
Large, physician-owned group practices are gaining ground as a popular form of practice, even as the number of physicians in solo and small practices declines, and employment maintains its appeal. As physicians shift from owning private practices to employment in hospital systems, this countertrend is also taking place. Large group practices are growing in number, even as solo and small practices are in decline. Do large, physician-owned groups bring benefits that beat employment? And how do large groups compare with smaller practices and new opportunities, such as private equity? You’ll find some answers here.
A new deep learning model is over 90% accurate in detecting protruding colonic lesions observed through capsule endoscopy, and it requires a fraction of the time endoscopists typically spend analyzing a full capsule exam, researchers have found. “I believe artificial intelligence will increase the use of capsule endoscopy, which is a very useful and noninvasive screening endoscopy tool,” Miguel Mascarenhas, MD, a gastroenterologist at SÃo JoÃo University Hospital, in Porto, Portugal,…
metaMe Health, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for Regulora®, the first FDA-authorized treatment of any kind specifically for abdominal pain associated with irritable bowel syndrome (IBS) in adults. Treatment of abdominal pain associated with IBS is poised for a fundamental shift in clinical practice. The COVID-19 pandemic has prevented patients from engaging in many of the activities of daily living and has led to increases in pain and psychological distress due to IBS-related symptoms (1). This has created a growing unmet medical need for self-administered behavioral therapy options to treat IBS.
The World Health Organization officially declared the spread of COVID-19 a pandemic in March 2020. One year later, the global count of COVID-19 cases is approaching 120 million, and the US count is close to 30 million, according to a data dashboard from the Center for Systems Science and Engineering at Johns Hopkins University. Deaths from the disease have surpassed 2.6 million worldwide, with nearly 530,000 in the United States.
The American College of Gastroenterology published an update to the association’s 2013 clinical guidelines on the diagnosis and management of gastroesophageal reflux disease.